Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Cash & Equivalents (2021 - 2025)

Lucid Diagnostics (LUCD) has disclosed Cash & Equivalents for 5 consecutive years, with $47.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents rose 226.68% year-over-year to $47.3 million, compared with a TTM value of $47.3 million through Sep 2025, up 226.68%, and an annual FY2024 reading of $22.4 million, up 18.32% over the prior year.
  • Cash & Equivalents was $47.3 million for Q3 2025 at Lucid Diagnostics, up from $31.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $53.7 million in Q4 2021 and bottomed at $21336.0 in Q3 2021.
  • Average Cash & Equivalents over 5 years is $25.9 million, with a median of $24.9 million recorded in 2024.
  • Peak annual rise in Cash & Equivalents hit 126137.35% in 2022, while the deepest fall reached 58.11% in 2022.
  • Year by year, Cash & Equivalents stood at $53.7 million in 2021, then tumbled by 58.11% to $22.5 million in 2022, then decreased by 15.92% to $18.9 million in 2023, then rose by 18.32% to $22.4 million in 2024, then skyrocketed by 111.7% to $47.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for LUCD at $47.3 million in Q3 2025, $31.1 million in Q2 2025, and $25.2 million in Q1 2025.